http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
-
Zai Lab Announces Participation in January Investor Conferences
-
Zai Lab Limited (ZLAB) Reports Interim Overall Survival Data for ZEJULA
-
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
-
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
-
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
-
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
-
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
-
Zai Lab Announces Participation in November Investor Conferences
-
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
-
Zai Lab Launches its first Trust Report
-
Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
-
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeti
-
Zai Lab Announces Participation in September Investor Conferences
-
Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates
-
Zai Lab Limited (ZLAB) Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
-
Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022
-
Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs
-
Zai Lab Limited (ZLAB) Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis
-
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis
-
Zai Lab Limited (ZLAB) Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
-
Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
-
Zai Lab (ZLAB) Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
-
Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
-
Zai Lab Limited (ZLAB) and Novocure (NVCR) Report Phase 2 Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint
-
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
-
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
-
Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference
-
Zai Lab Announces Upcoming Presentations at June Investor Conferences
-
Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022
-
Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates
-
Zai Lab Limited (ZLAB) Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART in Adults with Primary Immune Thrombocytopenia
-
Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
-
Turning Point (TPTX) and Zai Lab (ZLAB) Report Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
-
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
-
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
-
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
-
Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022
-
Zai Lab Plants a Tree for Every Employee on Earth Day 2022
-
Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting
-
Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022
-
Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
-
Zai Lab Limited (ZLAB) Appoints Josh Smiley as Chief Operating Officer
-
Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
-
Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
-
Zai Lab Limited (ZLAB) Granted Breakthrough Therapy Designation for Repotrectinib in China
-
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China
